These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 33747548)

  • 1. Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes.
    Lo CWH; Fei Y; Cheung BMY
    Card Fail Rev; 2021 Mar; 7():e04. PubMed ID: 33747548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH; Udell JA; Filion KB
    Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.
    Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Wittmann I; Kempler P
    Diabetes Ther; 2018 Oct; 9(5):2133-2141. PubMed ID: 30120754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
    Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
    Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
    Shin JI
    Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P; Acharya T
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
    Avogaro A; Delgado E; Lingvay I
    Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.